PROCÉDÉS DE TRAITEMENT DE LA LEUCÉMIE LYMPHOCYTAIRE CHRONIQUE ET UTILISATION DE BIOMARQUEURS EN TANT QUE PRÉDICTEUR DE SENSIBILITÉ CLINIQUE À DES THÉRAPIES IMMUNOMODULATRICES
A method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having CLL； administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample； determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample； and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.
